Chemotherapy with trifluridine/tipiracil prolongs progression-free survival time and improves quality of life. A case report of 59-year-old woman with metastatic rectal cancer Case report

Article Sidebar

PDF


Published: Mar 31, 2020
DOI: https://doi.org/10.24292/01.OR.120310320
Keywords:
rectal cancer, chemotherapy, trifluridine/tipiracil, progression-free survival, quality of life

Main Article Content

Beata Kania-Zembaczyńska
Oncology and Hematology Department, Beskid Oncology Centre – John Paul II Memorial City Hospital in Bielsko-Biala

Abstract

The paper presents a clinical case of a patient with a long-term response to IV line chemotherapy with trifluridine/tipiracil. The treatment allowed to maintain a good quality of life with acceptable side effects

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Kania-Zembaczyńska B. Chemotherapy with trifluridine/tipiracil prolongs progression-free survival time and improves quality of life. A case report of 59-year-old woman with metastatic rectal cancer. OncoReview [Internet]. 2020Mar.31 [cited 2024Nov.22];10(1(37):18-2. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/1078
Issue
Vol 10 No 1(37) (2020)
Section
CARDIO-ONCOLOGY
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. European Medicines Agency. European public assessment report (EPAR) for Lonsurf. 2016. http://www.ema.europa.eu.
2. Lenz HJ, Stintzing S, Loupakis F. TAS-102, a novel antitumor agent: a review of the mechanism of action. Cancer Treatment Rev. 2015; 41: 777-83.
3. Mayer R, Van Cutsem E, Falcone A et al.; RECOURSE Study Group. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015; 372: 1909-19.
4. Funaioli C, Longobardi C, Martoni AA. The impact of chemotherapy on overall survival and quality of life of patients with metastatic colorectal cancer: a review of phase III trials. J Chemother. 2008; 20: 14-27.
5. Van Cutsem E, Falcone A, Garcia-Carbonero R et al. Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial. ESMO Open. 2017; 2(5): e000261.